Lilly : FDA Approves Zepbound For Chronic Weight Management, New Option For Treatment Of Obesity

(RTTNews) - Eli Lilly and Co. (LLY) said that the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for Chronic Weight Management, a new option for the treatment of Obesity or Overweight with weight-related medical problems.

Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP or glucose-dependent insulinotropic polypeptide and GLP-1 or glucagon-like peptide-1, to tackle an underlying cause of excess weight, the company said in a statement.

Zepbound is indicated for adults with obesity or those who are overweight and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.

The company advised that Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines, and it has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis.

Tirzepatide is under regulatory review for weight management in Europe, China, the United Kingdom and several additional markets.

For More Such Health News, visit rttnews.com